CORT
Corcept Therapeutics advances cortisol modulation therapies focused on treating serious diseases by targeting the glucocorticoid receptor. The company conducts research and clinical development across endocrinology, oncology, metabolism, and neurology, aiming to unlock the therapeutic potential of cortisol modulation. Based in the United States, it communicates a commitment to scientific innovation and patient health through its pipeline and scientific publications.
No recent deals for this company.